未名醫藥(002581.SZ)2020年度預虧9976.23萬-19951.46萬元
格隆匯 1 月 28日丨未名醫藥(002581.SZ)公佈,預計2020年度歸屬於上市公司股東的淨虧損9976.23萬元-19951.46萬元,上年同期盈利6338.35萬元,扣除非經常性損益後的淨虧損8959.11萬元-17917.22萬元。
2020年公司生產情況受新冠肺炎疫情影響較為嚴重,由於國內各地區疫情階段性反覆,公司上下游企業復工緩慢,加之疫情影響導致各級醫療終端門診量減少,處方藥終端總體需求下降,同時受醫藥改革等宏觀政策、經濟下行等不利因素疊加,主營業務收入較上期有明顯減少。
公司根據《企業會計準則第8號—資產減值》、《會計監管風險提示第8號—商譽減值》的相關要求,公司預計需計提商譽減值金額約1000萬元至2000萬元。最終商譽減值計提的金額將由公司聘請的具備證券期貨從業資格的評估機構及審計機構進行評估和審計後確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.